Share ownership Ipsen

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris Other stock markets 12:44:28 10/03/2026 +03			5-day change	1st Jan Change
161.70 ^EUR	+4.86%		+0.56%	+35.88%

03-09	Hutchmed (China) says Ipsen initiates market withdrawal and recall of Tazverik in China	RE
03-09	Hutchmed announces update on licensed oncology product Tazverik in China	RE

Share class: Ipsen

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	83,814,526	34,829,783 ( 41.56 %)	1,116,316 ( 1.332 %)	41.56 %

Major shareholders: Ipsen

Name	Equities	%	Valuation
Estate of Henri Beaufour 26.03 %	21,816,679	26.03 %	3 571 M €
Anne Beaufour 26.03 %	21,816,679	26.03 %	3 571 M €
Schwabe Family 4.577 %	3,836,263	4.577 %	628 M €
IPSEN 1.318 %	1,105,073	1.318 %	181 M €
Arca Fondi SGR SpA 0.1924 %	161,263	0.1924 %	26 M €
Candriam SCA 0.166 %	139,107	0.166 %	23 M €
Marc M. P. de Garidel 0.1652 %	138,501	0.1652 %	23 M €
Lightman Investment Management Ltd. 0.1619 %	135,700	0.1619 %	22 M €
State Street Global Advisors Ltd. 0.153 %	128,249	0.153 %	21 M €
Sjunde AP-fonden 0.1034 %	86,684	0.1034 %	14 M €
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Ativo Capital Management LLC 0.0116 %	38,765	0.0116 %	2 M €
Yousif Capital Management LLC 0.001668 %	5,593	0.001668 %	228 888 €

Breakdown by shareholder type

Individuals	30.88%
Other	26.03%
Institutional	1.91%
Ipsen SA	1.32%
Unknown	39.87%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals	30.88%
France	27.65%
United Kingdom	0.33%
Italy	0.21%
Luxembourg	0.19%
Sweden	0.17%
Germany	0.12%
United States	0.11%
New Zealand	0.07%
Austria	0.05%
Finland	0.05%
Ireland	0.05%
Belgium	0.05%
Norway	0.04%
Switzerland	0.04%
Canada	0.03%
Liechtenstein	0.02%
Denmark	0.02%
Japan	0.01%
Estonia	0.01%
Spain	0.01%
Hong Kong	0.01%

Based on 1000 largest holdings

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).

Employees

5,535

Sector

Pharmaceuticals

Calendar

04-16 - Earnings release - Q1 2026

More about the company